You just read:

Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA® (aflibercept) Injection for Patients with Wet AMD

News provided by

Regeneron Pharmaceuticals, Inc.

Dec 11, 2017, 06:00 EST